



Bangalore, October 16th, 2008

Biocon's h1 fy '09 sustains growth in challenging conditions

Revenues Rs. 734 crores (Including AxiCorp) : Revenues Rs. 593 crores (Excluding AxiCorp)

EBITDA Rs. 168 crores. PAT Rs. 100 crores (Excluding MTM Loss of Rs. 60 crores)

Biocon Limited today announced its financial performance for the half year ending September 30th, 2008.

PERFORMANCE HIGHLIGHTS:

- Group Revenues (including AxiCorp) increased 33% from Rs. 553 crores in H1 '08 to Rs. 734 crores in H1 '09. Pharma sales (excluding licensing income and Axicorp) registered 21% growth bolstered by a 36% growth in our retail healthcare business.
- Syngene had a strong quarter delivering 21% sales growth on a QoQ basis in FY'09 and 9% YoY growth in H1 FY'09.
- AxiCorp made a modest debut in the Group's profitability but contributed Rs. 141 crores to the top line.
- Licensing income in H1 was moderate at Rs. 3 crores. This is expected to increase significantly in H2.
- Biocon's balance sheet remains strong. Net cash as on 30th September '08 was Rs. 30 crores (Gross - Rs. 355 crores) .
- Clinical development of the company's lead programs viz. IN105 (Oral Insulin) and T1h (Anti CD6 Monoclonal antibody) are progressing well. Oral Insulin will commence Phase III Clinical Trials shortly.
- Biocon filed 11 new patents in Q2 '09 bringing the total tally to 892 filed and 166 granted patents.
- Biocon has been ranked the 7th largest global employer in the Biotechnology sector by a reputed US trade journal.

Commenting on the results, Kiran Mazumdar-Shaw, Chairman & Managing Director, Biocon Limited, said:

"Biocon's H1 '09 performance has shown resilience despite being impacted by Rupee



volatility which has seen us make a Mark to Market provision of Rs. 60 crores. At a time when global businesses are challenged with an economic downturn, we believe that our strong financial base gives us a significant advantage. Q2 FY'09 has seen us deliver the highest ever revenues across all divisions. Our API business has registered a 21% YoY growth bolstered by 36% growth in our retail branded formulations. Syngene has had a particularly strong quarter delivering its best ever sales and operating profit.

Clinigene continues to carve a niche for itself in the CRO segment where India is emerging as an important global destination for clinical development.

We are making excellent progress on the research front with our Oral Insulin IN 105 program, set to enter Phase III Clinical trials and our Anti-CD6 Monoclonal antibody nearing the completion phase for patient enrollment.

We remain confident of delivering a good performance for the year.”

CORPORATE DEVELOPMENTS:

NeoBiocon launched Abraxane in the GCC markets on 9th October, 2008

Biocon's JV in Abu Dhabi, NeoBiocon announced the launch of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in the UAE for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy.

ABRAXANE is now available in the UAE as a single-use 100 mg vial (as a lyophilized powder, to be reconstituted for intravenous administration).

The UAE is witnessing an alarming increase in Breast Cancer which is mirrored across the GCC region with 20% of women between the age group of 35-65 exhibiting a risk propensity for Breast Cancer.

In August 2007, Abraxis established a licensing agreement with Biocon for the commercialization of ABRAXANE in India. Under the terms of the agreement, Biocon has the right to market ABRAXANE in India, Pakistan, Bangladesh, Sri Lanka, the United Arab Emirates, Saudi Arabia, Kuwait and certain other South Asian and Persian Gulf countries. Subsequently, Abraxis received approval in October 2007 from India's Drug Control General to market ABRAXANE in India.

Biocon is ranked 7th largest global employer in the Biotechnology sector by Med Ad News

Biocon has been ranked as the 7th largest employer amongst the top global biotechnology companies, according to a report released by Med Ad News. The report takes into consideration drug based firms, as these companies provide the best numbers to track the progress of the sector. Companies have been ranked by number of employees and Biocon Limited is the only Asian company to feature in the Top 25 at Number 7.

BIO 2008, held in San Diego recently, stated that the global biotechnology industry will be a \$100 billion annual business by 2010. The actual revenue has reached \$85 billion in



2007. There are close to 5000 biotech companies across the globe. The top 25 biotech companies represent 62 percent of all biotech sales and probably over 90 percent of income. Biocon has been ranked the 20th leading global Biotech company and the only Asian company to feature in the Top 25.

Note: The discussions in this release reflect the audited financial performance of Biocon Limited based on Indian GAAP on a consolidated basis. This considers the financial performance of Biocon Limited, its wholly owned subsidiaries Syngene International Limited Clinigene International Limited and Biocon SA and its 71% subsidiary Axicorp GmbH and its 51% joint venture Biocon Biopharmaceuticals Private Limited.

About Biocon

Established in 1978, Biocon Limited is one of India's premier biotechnology companies. Biocon, its two wholly owned subsidiary companies, Syngene International Ltd and Clinigene International Ltd and its Joint Venture Company Biocon Biopharmaceuticals Pvt Ltd form a fully integrated biotechnology enterprise, specializing in biopharmaceuticals, custom research, and clinical research. With successful initiatives in clinical development, bioprocessing and global marketing, Biocon delivers products and solutions to partners and customers across the globe. Visit us at www.biocon.com

BIOCON GROUP

FINANCIALS

H1 FY 2009 vs H1 FY 2008

FACT SHEET

BIOCON LIMITED (CONSOLIDATED)		
BALANCE SHEET		(Rs. Millions)
Particulars	As at 30-Sep-08	As at 31-Mar-08
<u>SOURCES OF FUNDS</u>		
Share Capital	1,000	500
Reserves & Surplus	14,275	14,341
Total Shareholder's Funds	15,275	14,841
Minority interest	262	-73
Deferred Tax Liability	450	465
Secured Loans	2,311	1,351
Unsecured Loans	1,563	1,200
Total Loan Funds	3,874	2,551
Total	19,861	17,784
<u>APPLICATION OF FUNDS</u>		
Fixed Assets (Net)	12,641	10,419
Intangible Assets	457	276
Investments	3,800	4,748
Inventories	2,654	1,790
Sundry debtors	3,592	2,591
Cash and bank balances	200	96
Loans and advances	862	869
Total Current Assets, Loans & Advances	7,308	5,346
Less: Current liabilities and provisions	4,345	3,005
Net Current assets	2,963	2,341
Total	19,861	17,784

BIOCON LIMITED (CONSOLIDATED)
PROFIT & LOSS STATEMENT
(Rs. Millions)

Particulars	H1 WITH AXICORP FY 2009	H1 WITHOUT AXICORP FY 2009	H1 FY 2008	Variance	Full Year ended March 31, 2008
INCOME					
Biopharmaceuticals*	6,103	4,707	4,179	13%	8,323
Contract research	959	959	862	11%	1,755
	7,062	5,666	5,041	12%	10,078
Enzymes	-	-	457	-	460
Total Sales	7,062	5,666	5,498	3%	10,538
Other income	280	267	29	-	364
Total Income / Revenues	7,342	5,933	5,527	7%	10,902
EXPENDITURE					
Material & Power Costs	3,927	2,780	2,645	5%	5,116
Staff costs	744	639	594	8%	1,127
Research & Development	260	260	211	23%	471
Forex Loss/ (gain)	96	96	7	1271%	(23)
Other Expenses	633	527	470	12%	861
Manufacturing, staff & other exps	5,660	4,302	3,927	10%	7,552
PBDIT /EBIDTA	1,682	1,631	1,600	2%	3,350
Interest and finance charges	79	72	54		102
PBDT	1,603	1,559	1,546	1%	3,248
Depreciation	543	518	454		939
PBT	1,060	1,041	1,092	-5%	2,309
Taxes	76	75	52		129
PROFIT FOR THE PERIOD	984	966	1,040	-7%	2,180
Add/(less): Minority interest	16	24	28		65
Profit before Exceptional Items	1,000	990	1,068	-7%	2,245
Exceptional Item - Net of Tax	-	-	-		2,394
Exceptional Item (MTM Provision - Forex) - Net of tax	600	600	-		-
NET PROFIT (PAT)	400	390	1,068	-63%	4,639
EPS on issued capital Rs. (before exceptional items)				-7%	11.2

* Includes Technical licensing fee Rs. 30 (H1 FY 09), Rs. 322 (H1 FY 08), Rs. 448 (FY 08)

Note: The figures are rounded off to nearest million, percentages are based on absolute numbers

BIOCON LIMITED (CONSOLIDATED)		
STATEMENT OF CASH FLOWS		(Rs. Millions)
Particulars	Quarter ended September 30, 2008	Full Year ended March 31, 2008
<u>I. Cash Flow from Operating Activities</u>		
Net profit before tax	493	5,387
Less/Add: non-cash items/ items required separately		
Depreciation	543	939
Exceptional Income Considered Separately	-	(3,078)
Provision for MTM Loss	600	-
Others	(34)	1
Changes in working capital and other provisions	(102)	172
Cash generated from operations	900	3,421
Tax paid (net of refunds)	(127)	(243)
Net Cash provided by operating activities	773	3,178
<u>II. Cash Flow from Investing Activities</u>		
Fixed Assets	(2,752)	(2,325)
Exceptional Income, net	-	2,668
Interest / dividend received	147	164
Investments	1,276	(3,909)
Net cash used for investing activities	(1,329)	(3,402)
<u>III. Cash Flows from Financing Activities</u>		
Borrowings and other financing activities	660	232
Net Cash provided/(used) for financing activities	660	232
<u>IV. Net Change in Cash and Cash Equivalents (I+II+III)</u>		
	104	8
<u>V. Cash & Cash Eq. at the beginning of the year</u>		
	92	86
<u>VI. Cash and Cash Eq. at the end of the year (IV+V)</u>		
	196	94